Cited by 449RNA Interference and Gene DeliveryCytokine Signaling Pathways and InteractionsDNA and Nucleic Acid Chemistry

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Open access

Hong, David, Kurzrock, Razelle, Kim, Youngsoo, Woessner, Richard, Younes, Anas, Nemunaitis, John, Fowler, Nathan, Zhou, Tianyuan, Schmidt, Joanna, Jo, Minji, Lee, Samantha J., Yamashita, Mason, Hughes, Steven G., Fayad, Luis, Piha-Paul, Sarina, Nadella, Murali V. P., Mohseni, Morvarid, Lawson, Deborah, Reimer, Corinne, Blakey, David C., Xiao, Xiaokun, Hsu, Jeff, Revenko, Alexey, Monia, Brett P., MacLeod, A. Robert·2015·Science Translational Medicine

DOI 10.1126/scitranslmed.aac5272PMC PMC5279222

Open this paper in CoChat — free account

Abstract

Next-generation sequencing technologies have greatly expanded our understanding of cancer genetics. Antisense technology is an attractive platform with the potential to translate these advances into improved cancer therapeutics, because antisense oligonucleotide (ASO) inhibitors can be designed on the basis of gene sequence information alone. Recent human clinical data have demonstrated the potent activity of systemically administered ASOs targeted to genes expressed in the liver. We describe the preclinical activity and initial clinical evaluation of a class of ASOs containing constrained ethyl modifications for targeting the gene encoding the transcription factor STAT3, a notoriously difficult protein to inhibit therapeutically. Systemic delivery of the unformulated ASO, AZD9150, decreased STAT3 expression in a broad range of preclinical cancer models and showed antitumor activity in lymphoma and lung cancer models. AZD9150 preclinical activity translated into single-agent antitumor activity in patients with highly treatment-refractory lymphoma and non-small cell lung cancer in a phase 1 dose-escalation study.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aac5272

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,560
IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples
Varghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome
Minegishi, Y., Saitō, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pašić, S., Stojković, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,075
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 934
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897
Oncogene Addiction
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity
Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P. E., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 724
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716

Show all 60 references

Sorted by citations

Items 101–200 of 449

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
Kim, Y., Jo, M., Schmidt, J., Luo, X., Prakash, T. P., Zhou, T., Klein, S., Xiao, X., Post, N. M., Yin, Z., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.009 · Cited by 81
Self-citation
Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
Jamroškovič, J., Doimo, M., Chand, K., Obi, I. R., Kumar, R., Brännström, K., Hedenström, M., Das, R. N., Akhunzianov, A., Deiana, M., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11232 · Cited by 80
STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Moreira, D., Adamus, T., Zhao, X., Su, Y.-L., Zhang, Z., White, S. V., Swiderski, P., Lu, X., DePinho, R. A., Pal, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1277 · Cited by 80
RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis
Zhu, H., Chen, K., Chen, Y., Liu, J., Zhang, X., Zhou, Y., Liu, Q., Wang, B., Chen, T., & Cao, X. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01033-8 · Cited by 80
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Ip, C. K. M., Ng, P. K., Jeong, K. J., Shao, S. H., Ju, Z., Leonard, P. G., Hua, X., Vellano, C. P., Woessner, R. D., Sahni, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06949-w · Cited by 77
Self-citation
The Emerging Role of Long Non-Coding RNAs in the Metastasis of Hepatocellular Carcinoma
Chen, X., Tang, F. R., Arfuso, F., Cai, W.-Q., Ma, Z., Yang, J., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom10010066 · Cited by 79
N4-acetylcytidine modification of lncRNA CTC-490G23.2 promotes cancer metastasis through interacting with PTBP1 to increase CD44 alternative splicing
Yu, X.-M., Li, S., Yao, Z.-T., Xu, J., Zheng, C., Liu, Z., Ding, P.-B., Jiang, Z., Wei, X., Zhao, L., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02628-3 · Cited by 81
STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
Jiang, M., & Li, B. (2022) · Cells · doi:10.3390/cells11193131 · Cited by 78
The strategies to cure cancer patients by eradicating cancer stem-like cells
Mai, Y., Su, J., Yang, C., Xia, C., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01867-y · Cited by 78
Gene Therapy for Neuropathic Pain through siRNA-IRF5 Gene Delivery with Homing Peptides to Microglia
Terashima, T., Ogawa, N., Nakae, Y., Sato, T., Katagi, M., Okano, J., Maegawa, H., & Kojima, H. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.007 · Cited by 79
Targeting splicing abnormalities in cancer
Agrawal, A. A., Yu, L., Smith, P. G., & Buonamici, S. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.010 · Cited by 79
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
Brachet‐Botineau, M., Polomski, M., Neubauer, H. A., Juen, L., Hédou, D., Viaud‐Massuard, M., Prié, G., & Gouilleux, F. (2020) · Cancers · doi:10.3390/cancers12010240 · Cited by 77
Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
Parakh, S., Ernst, M., & Poh, A. R. (2021) · Cancers · doi:10.3390/cancers13246228 · Cited by 77
Splicing factors: Insights into their regulatory network in alternative splicing in cancer
Du, J.-X., Zhu, G., Cai, J., Wang, B., Luo, Y., Chen, C., Cai, C.-Z., Zhang, S., Zhou, J., Fan, J., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.043 · Cited by 72
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 74
Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption
Mondala, P. K., Vora, A. A., Zhou, T., Lazzari, E., Ladel, L., Luo, X., Kim, Y., Costello, C. L., MacLeod, A. R., Jamieson, C. H. M., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2020.12.017 · Cited by 70
Self-citation
Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance
Zhao, Z., Li, T., Sun, L. L., Yuan, Y., & Zhu, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115425 · Cited by 71
Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment
Lin, F., Yin, S., Zhang, Z., Yu, Y., Fang, H., Liang, Z., Zhu, R., Zhou, H., Li, J., Cao, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.016 · Cited by 72
New Therapies in Head and Neck Cancer
Santuray, R. T., Johnson, D. E., & Grandis, J. R. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.006 · Cited by 67
Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer
Adewunmi, O., Shen, Y., Zhang, X. H.-F., & Rosen, J. M. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0045 · Cited by 73
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications
Yan, Y., Liu, S., Wen, J., He, Y., Duan, C., Nabavi, N., Ashrafizadeh, M., Sethi, G., Liu, L., & Ma, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02463-y · Cited by 71
The curious origins of angioimmunoblastic T-cell lymphoma
Cortés, J. R., & Palomero, T. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000261 · Cited by 65
Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies
Morgan, E. L., & Macdonald, A. (2020) · Viruses · doi:10.3390/v12090977 · Cited by 64
Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors
Dinakar, Y. H., Kumar, H., Mudavath, S. L., Jain, R., AJMEER, R., & Jain, V. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120996 · Cited by 65
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
MacLeod, A. R., & Crooke, S. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.957 · Cited by 61
Self-citation
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
Ohanian, M. N., Ashizawa, A. T., Garcia‐Manero, G., Pemmaraju, N., Kadia, T. M., Jabbour, E. J., Ravandi, F., Borthakur, G. M., Andreeff, M., Konopleva, M. Y., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30021-8 · Cited by 63
Antisense Oligonucleotide-Based Therapy of Viral Infections
Tarn, W., Cheng, Y., Ko, S.-H., & Huang, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122015 · Cited by 68
STAT3 and p53: Dual Target for Cancer Therapy
Pham, T., Park, H., Kim, J., Hong, J. T., & Yoon, D. (2020) · Biomedicines · doi:10.3390/biomedicines8120637 · Cited by 63
Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies
Anwar, S., Mir, F., & Yokota, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041130 · Cited by 65
Role of STAT3 in Genesis and Progression of Human Malignant Gliomas
Ouedraogo, Z. G., Biau, J., Kémény, J., Morel, L., Verrelle, P., & Chautard, E. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0103-0 · Cited by 63
Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
Odate, S., Veschi, V., Yan, S., Lam, N., Woessner, R. D., & Thiele, C. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1317 · Cited by 61
Self-citation
Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth
Sun, L., Yan, Y., Lu, H., Li, J., Wang, Z., Wang, K., Wang, L., Li, Y., Jiang, H., & Zhang, Y. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.10.006 · Cited by 61
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 65
Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications
Park, H., Lee, S.-H., Lee, J., Moon, H., & Ro, S. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813764 · Cited by 63
Self-citation
An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL
Mai, Y., Yu, J., Bartholdy, B., Xu-Monette, Z. Y., Knapp, E. E., Yuan, F., Chen, H., Ding, B. B., Yao, Z., Das, B. C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705814 · Cited by 57
Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy
Huang, T., Su, J.-C., Liu, C., Shiau, C., & Chen, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061234 · Cited by 60
Observing an Antisense Drug Complex in Intact Human Cells by in‐Cell NMR Spectroscopy
Schlagnitweit, J., Sandoz, S. F., Jaworski, A., Guzzetti, I., Aussenac, F., Carbajo, R. J., Chiarparin, E., Pell, A. J., & Petzold, K. (2019) · ChemBioChem · doi:10.1002/cbic.201900297 · Cited by 58
The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT
Ryan, M. R., Sohl, C. D., Luo, B., & Anderson, K. S. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0429 · Cited by 58
A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Park, W.-J., & Kim, M. J. (2023) · Cells · doi:10.3390/cells12081110 · Cited by 57
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
Zhou, H., Bai, L., Xu, R., McEachern, D., Chinnaswamy, K., Li, R., Wen, B., Wang, M., Yang, C., Meagher, J. L., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00155 · Cited by 56
Long Non-Coding RNA (lncRNA) in Oral Squamous Cell Carcinoma: Biological Function and Clinical Application
Tang, J., Fang, X., Chen, J., Zhang, H., & Tang, Z. (2021) · Cancers · doi:10.3390/cancers13235944 · Cited by 56
RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation
Oh, R. S., Haak, A. J., Smith, K. M. J., Ligresti, G., Choi, K. M., Xie, T., Wang, S., Walters, P., Thompson, M. A., Freeman, M., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.209932 · Cited by 57
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Proia, T. A., Singh, M., Woessner, R. D., Carnevalli, L. S., Bommakanti, G., Magiera, Ł., Srinivasan, S. S., Grosskurth, S. E., Collins, M. P., Womack, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1066 · Cited by 63
Self-citation
Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
Yasuhara, H., Yoshida, T., Sasaki, K., Obika, S., & Inoue, T. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00573-z · Cited by 57
Cancer stem cells: at the forefront of personalized medicine and immunotherapy
Fiori, M. E., Villanova, L., & Maria, R. D. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.006 · Cited by 55
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
Xiao, L., Tien, J. C.-Y., Vo, J. N., Tan, M., Parolia, A., Zhang, Y., Wang, L., Qiao, Y., Shukla, S. K., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0941 · Cited by 58
Self-citation
Human Bone Marrow-Derived Mesenchymal Stem Cells Promote the Growth and Drug-Resistance of Diffuse Large B-Cell Lymphoma by Secreting IL-6 and Elevating IL-17A Levels
Zhong, W., Zhu, Z., Xu, X., Zhang, H., Xiong, H., Li, Q., & Wei, Y. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1081-7 · Cited by 55
An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
Xu, S., Zhou, T., Doh, H. M., Trinh, K. R., Catapang, A., Lee, J. T., Braas, D., Bayley, N. A., Yamada, R. E., Vasuthasawat, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2799 · Cited by 55
Self-citation
Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics
Zhou, T., Kim, Y., & MacLeod, A. R. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3378-5_16 · Cited by 53
Self-citation
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Soldevilla, M. M., Meraviglia-Crivelli, D., Menon, A. P., & Pastor, F. (2018) · Pharmaceuticals · doi:10.3390/ph11040108 · Cited by 54
The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer
Takakura, K., Kawamura, A., Torisu, Y., Koido, S., Yahagi, N., & Saruta, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133331 · Cited by 54
The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
Witalisz‐Siepracka, A., Klein, K., Moser, B., & Stoiber, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947568 · Cited by 57
Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
Bosch‐Barrera, J., Sais, È., Cañete, N., Marruecos, J., Cuyàs, E., Izquierdo, Á., Porta, R., Haro, M., Brunet, J., Pedraza, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7900 · Cited by 54
Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options
Veschi, V., Verona, F., & Thiele, C. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00782 · Cited by 54
Benzyl Isothiocyanate (BITC) Induces Reactive Oxygen Species-dependent Repression of STAT3 Protein by Down-regulation of Specificity Proteins in Pancreatic Cancer
Kasiappan, R., Jutooru, I., Karki, K., Hedrick, E., & Safe, S. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746339 · Cited by 52
A New Perspective: Mitochondrial Stat3 as a Regulator for Lymphocyte Function
Rincón, M., & Pereira, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061656 · Cited by 57
Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance
Hashimoto, S., Hashimoto, A., Muromoto, R., Kitai, Y., Oritani, K., & Matsuda, T. (2022) · Cells · doi:10.3390/cells11162618 · Cited by 51
Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy
Shi, D., Tao, J., Man, S., Zhang, N., Ma, L., Guo, L., Huang, L., & Gao, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189207 · Cited by 51
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Frontzek, F., Staiger, A. M., Zapukhlyak, M., Xu, W., Bonzheim, I., Borgmann, V., Sander, P., Baptista, M. J., Heming, J.-N., Berning, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25405-w · Cited by 51
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice
Nuñez‐Durán, E., Aghajan, M., Amrutkar, M., Sütt, S., Cansby, E., Booten, S. L., Watt, A. T., Ståhlman, M., Stefan, N., Häring, H., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1128 · Cited by 49
Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease
Cansby, E., Nuñez‐Durán, E., Magnusson, E., Amrutkar, M., Booten, S. L., Kulkarni, N. M., Svensson, T., Borén, J., Marschall, H., Aghajan, M., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.12.004 · Cited by 50
Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer
Huang, C., Zhou, W., Bian, A., Zhang, Q., Miao, Y., Yin, X., Ye, J., Xu, S., Ti, C., Sun, Z., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0997 · Cited by 50
Targeting STAT3 in Cancer with Nucleotide Therapeutics
Lau, Y.-T. K., Ramaiyer, M. S., Johnson, D. E., & Grandis, J. R. (2019) · Cancers · doi:10.3390/cancers11111681 · Cited by 49
Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets
Barresi, V., Musmeci, C., Rinaldi, A., & Condorelli, D. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168875 · Cited by 52
Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
Cavalieri, S., Rivoltini, L., Bergamini, C., Locati, L. D., Licitra, L. F., & Bossi, P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.03.003 · Cited by 47
Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
Ni, Y., Low, J. T., Silke, J., & O’Reilly, L. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835997 · Cited by 47
Podocyte-Parietal Epithelial Cell Interdependence in Glomerular Development and Disease
Bronstein, R. D., Pace, J. A., Gowthaman, Y., Salant, D. J., & Mallipattu, S. K. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000104 · Cited by 46
STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer
Li, X., Jiang, W., Dong, S., Li, W.-C., Zhu, W., & Zhou, W. (2022) · Biomolecules · doi:10.3390/biom12101450 · Cited by 41
STAT3beta, a distinct isoform from STAT3
Zhang, H., Yang, P.-L., Li, E., & Xu, L. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.02.006 · Cited by 45
Long noncoding RNA loss in immune suppression in cancer
Hu, Q., Egranov, S. D., Lin, C., & Yang, L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107591 · Cited by 46
STAT3: A key signaling molecule for converting cold to hot tumors
Hu, R., Han, Q., & Zhang, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.035 · Cited by 45
RNA Therapeutics: How Far Have We Gone?
Coutinho, M. F., Matos, L., Santos, J. I., & Alves, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-19966-1_7 · Cited by 45
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review
Shen, Y., Thng, D. K. H., Wong, A. L. A., & Toh, T. B. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00512-8 · Cited by 47
Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment
Lin, J.-C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010075 · Cited by 43
An Unexpected Role of Hyaluronic Acid in Trafficking siRNA Across the Cellular Barrier: The First Biomimetic, Anionic, Non‐Viral Transfection Method
Paidikondala, M., Rangasami, V. K., Nawale, G. N., Casalini, T., Perale, G., Kadekar, S., Mohanty, G., Salminen, T., Oommen, O. P., & Varghese, O. P. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201900099 · Cited by 43
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes
Setoguchi, K., Cui, L., Hachisuka, N., Obchoei, S., Shinkai, K., Hyodo, F., Kato, K., Wada, F., Yamamoto, T., Harada‐Shiba, M., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.09.004 · Cited by 42
Long Non-coding RNAs as Communicators and Mediators Between the Tumor Microenvironment and Cancer Cells
Chen, D., Lu, T., Tan, J., Li, H. R., Wang, Q., & Wei, L.-Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00739 · Cited by 42
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide
Oweida, A., Mueller, A. C., Piper, M., Milner, D. C., Court, B. V., Bhatia, S., Phan, A. V., Bickett, T. E., Jordan, K. R., Proia, T. A., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02701-w · Cited by 44
Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study
Nishina, T., Fujita, T., Yoshizuka, N., Sugibayashi, K., Murayama, K., & Kuboki, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055718 · Cited by 40
STAT3: Key targets of growth-promoting receptor positive breast cancer
Jiang, R., Zhu, J., Zhang, H., Yuan, Y. J., Dong, Z.-X., Zhou, H., & Wang, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03541-9 · Cited by 43
Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells
Liao, C., Chen, L., Luethy, A., Kim, Y., Kani, K., MacLeod, A. R., & Gross, M. E. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0138 · Cited by 40
Self-citation
Neue Modalitäten für schwierige Zielstrukturen in der Wirkstoffentwicklung
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie · doi:10.1002/ange.201611914 · Cited by 40
Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment
Gaggianesi, M., Franco, S. D., Pantina, V. D., Porcelli, G., D’Accardo, C., Verona, F., Veschi, V., Colarossi, L., Faldetta, N., Pistone, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702642 · Cited by 43
Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models
Kim, W. G., & Cheng, S.-Y. (2018) · Hormones and Cancer · doi:10.1007/s12672-017-0320-7 · Cited by 39
Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities
Robinson, T. J., Freedman, J. A., Abo, M. A., Deveaux, A. E., LaCroix, B. L., Patierno, B. M., George, D. J., & Patierno, S. R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2445 · Cited by 40
Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)
Somasundaram, N., Lim, J. Q., Ong, C. K., & Lim, S. T. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0717-6 · Cited by 39
Myeloid-Derived Suppressor Cell Differentiation in Cancer: Transcriptional Regulators and Enhanceosome-Mediated Mechanisms
Fultang, N., Li, X., Li, T., & Chen, Y. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619253 · Cited by 38
Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3
Servais, F., Kirchmeyer, M., Hamdorf, M., Minoungou, N., Rose‐John, S., Kreis, S., Haan, C., & Behrmann, I. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.03.007 · Cited by 37
Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3
Hall, J., Zhang, Z., Bhattacharya, S., Wang, D., Alcantara, M. B., Liang, Y., Swiderski, P. M., Forman, S. J., Kwak, L. W., Vaidehi, N., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102137 · Cited by 39
Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
Weimbs, T., Shillingford, J. M., Torres, J. A., Kruger, S. L., & Bourgeois, B. C. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy089 · Cited by 37
Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases.
Mehta, M., Paudel, K., Shukla, S., Allam, V., Kannaujiya, V., Panth, N., Das, A., Parihar, V., Chakraborty, A., Ali, M., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.010 · Cited by 32
Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma
Mohanty, A. R., Sandoval, N., Phan, A. T., Nguyen, T. V., Chen, R. W., Budde, L. E., Mei, M. G., Popplewell, L. L., Pham, L. V., Kwak, L. W., et al. (2018) · Blood · doi:10.1182/blood-2018-05-851667 · Cited by 40
Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges
Arshad, S., Naveed, M., Ullia, M., Javed, K., Butt, A. J., Khawar, M., & Amjad, F. (2020) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2018-0160 · Cited by 37
Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy
Velasco, M. A. D., Kura, Y., Sakai, K., Hatanaka, Y., Davies, B. R., Campbell, H., Klein, S., Kim, Y. S., MacLeod, A. R., Sugimoto, K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122688 · Cited by 37
Self-citation
Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells
Zhao, C., Yang, L., Zhou, F., Yu, Y., Du, X., Xiang, Y., Li, C., Huang, X., Xie, C., Liu, Z., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1271-y · Cited by 37
Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly
Betsch, A., Rutgeerts, O., Fevery, S., Sprangers, B., Verhoef, G. E. G., Dierickx, D., & Beckers, M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.006 · Cited by 35
Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes
Dankner, M., Maritan, S. M., Priego, N., Kruck, G., Nkili-Meyong, A. A., Nadaf, J., Zhuang, R., Annis, M. G., Zuo, D., Nowakowski, A., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae013 · Cited by 34
Beyond ribose and phosphate: Selected nucleic acid modifications for structure–function investigations and therapeutic applications
Liczner, C., Duke, K., Juneau, G., Egli, M., & Wilds, C. J. (2021) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.17.76 · Cited by 34
Harnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35
Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3
Hu, Y., Liu, F., Jia, X., Wang, P., Gu, T., Liu, H., Liu, T., Wei, H., Chen, H., Zhao, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01817-2 · Cited by 34

Authors: Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., Lee, S. J., Yamashita, M., Hughes, S. G., Fayad, L., Piha-Paul, S., Nadella, M. V. P., Mohseni, M., Lawson, D., Reimer, C., Blakey, D. C., Xiao, X., Hsu, J., Revenko, A., Monia, B. P., & MacLeod, A. R.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Moores Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
AstraZeneca (United States) (US)
Memorial Sloan Kettering Cancer Center (US)
Mary Crowley Cancer Research Center (US)
AstraZeneca (United Kingdom) (GB)
Corresponding author: Hong, David
Kurzrock, Razelle
Kim, Youngsoo
MacLeod, A. Robert
ORCID: Hong, David
Kurzrock, Razelle
Kim, Youngsoo
Younes, Anas
Nemunaitis, John
Fowler, Nathan
Zhou, Tianyuan
Jo, Minji
Lee, Samantha J.
Hughes, Steven G.
Piha-Paul, Sarina
Mohseni, Morvarid
Lawson, Deborah
Reimer, Corinne
Hsu, Jeff
Revenko, Alexey
Monia, Brett P.
MacLeod, A. Robert
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2015-11-18
Volume: 7
Issue: 314
Pages: 314ra185-314ra185
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aac5272
PMC: PMC5279222
OpenAlex: W2174791834
Cited by: 445
References: 60
Citations by year: 2026: 27 · 2025: 29 · 2024: 43 · 2023: 45 · 2022: 41 · 2021: 48 · 2020: 46 · 2019: 52 · 2018: 50 · 2017: 33 · 2016: 30 · 2015: 1
FWCI: 16.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.sciencemag.org/about/science-licenses-journal-article-reuse (vor, 366 d)
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Isis Pharmaceuticals Inc.
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
Keywords: antisense oligonucleotides, STAT3 inhibition, lymphoma, non-small cell lung cancer, anticancer activity, treatment-refractory cancer, systemic drug delivery, transcription factor inhibition
MeSH terms: Adult, Aged, Aged, 80 and over, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Lymphoma, Male, Mice, Inbred BALB C, Mice, Nude, Middle Aged, Oligonucleotides, Time Factors, Down-Regulation, Gene Expression Regulation, Neoplastic, Oligonucleotides, Antisense, Mice, SCID, Mice, Inbred NOD, Treatment Outcome, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Cell Proliferation, STAT3 Transcription Factor, Gene Knockdown Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks